Clinical Trial Update: A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for relmacabtagene autoleucel infusion in relapsed or refractory B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Lymphoma

Drugs mentioned

• Relmacabtagene Autoleucel (relmacabtagene autoleucel)

Snippet

Sponsor: Changhai Hospital | Conditions: Relapsed or Refractory B-cell Lymphoma | Phase 4 | Status: NOT_YET_RECRUITING